A case report on gastrointestinal mucormycosis

Authors

  • B. Vijay Kumar Department of General Medicine, Yashoda Hospitals, Secunderabad, Telangana, India
  • G. Vamshi Nandan Rao Department of General Medicine, Yashoda Hospitals, Secunderabad, Telangana, India
  • Mettu Veena Department of General Medicine, Yashoda Hospitals, Secunderabad, Telangana, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20253358

Keywords:

Gastric mucormycosis, Isavuconazole, Laparotomy, Sleeve gastrectomy, Acute kidney injury, Fungal infection

Abstract

Mucormycosis is a rare but often fatal opportunistic fungal infection and gastrointestinal (GI) mucormycosis is an uncommon subtype associated with high mortality, particularly in immunocompromised individuals such as those with diabetes, malignancy or organ failure. A 57-year-old man reported with symptoms of fever, jaundice, altered mentation and generalised weakness. He was intubated and managed in ICU for sepsis, MODS and encephalopathy. Investigations revealed hyperglycaemia, renal dysfunction and leucocytosis and were managed with several intravenous antibiotics and other supportive care, sustained low-efficiency dialysis (SLED) was performed due to hyperkalemia and metabolic acidosis, along with acute kidney injury (AKI). After an endoscopy showed an ulcerated tumor in the stomach fundus, a sleeve gastrectomy and laparotomy were carried out. Histopathology confirmed gastric mucormycosis with angioinvasion. Initial treatment with liposomal Amphotericin B (300 mg, IV, once daily) was given and stopped due to acute kidney injury and replaced by Isavuconazole (200 mg, oral, once daily). Multidisciplinary care led to clinical improvement and the patient was discharged in stable condition. Prompt endoscopic evaluation, surgical intervention, and timely antifungal therapy, especially Isavuconazole when Amphotericin B is contraindicated, can significantly enhance survival and multidisciplinary approach is vital in managing such complex infections.

Metrics

Metrics Loading ...

References

Afroze SN, Korlepara R, Rao GV, Madala J. Mucormycosis in a diabetic patient: A case report with an insight into its pathophysiology. Contemp Clin Dent. 2017;8:662-6. DOI: https://doi.org/10.4103/ccd.ccd_558_17

Jeong W, Keighley C, Wolfe R, Lee W L, Slavin M A, Kong DCM, et al. The epidemiology and clinical manifestations of mucormycosis: a system-atic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25:26–34. DOI: https://doi.org/10.1016/j.cmi.2018.07.011

Mankar SD, Waditake P, Jejurkar P. Review on Mucormycosis: It is a life Threatening infection. Asian J Res Pharm Sci. 2021;11:316-8. DOI: https://doi.org/10.52711/2231-5659.2021.00049

Serris A, Danion F, Lanternier F. Disease Entities in Mucormycosis. J Fungi (Basel). 2019;14;5:23. DOI: https://doi.org/10.3390/jof5010023

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405-21.

Rathi C, Shinde RK, Dighe SP, Lamture Y, Mahawar R. Gastric Necrosis: A Rare Complication of Gastric Mucormycosis. Cureus. 2023;15:e35810. DOI: https://doi.org/10.7759/cureus.35810

Saini H, Mann H, Saini I, Bhanot N, Kelly K, Rana S. Isolated cerebral mucormycosis: A case discussion. IDCases. 2023 ;33:e01821. DOI: https://doi.org/10.1016/j.idcr.2023.e01821

Addasi Y, Nguyen AH, Sabri A, Ahmad F, Rangray R, Velagapudi M. Gastrointestinal Mucormycosis: A Clinical Review. Gastroenterol Res. 2023;16:249-53. DOI: https://doi.org/10.14740/gr1662

Naqvi HA, Nadeem Yousaf M, Chaudhary FS, Mills L. Gastric Mucormycosis: An Infection of Fungal Invasion into the Gastric Mucosa in Immunocompromised Patients. Case Rep Gastrointest Med. 2020;2020:8876125. DOI: https://doi.org/10.1155/2020/8876125

Pravalika L, Marapaka P. Diagnosis of invasive Mucormycosis on Histopathological examination at a tertiary referral hospital. IP Arch Cytol Histopathol Res. 2022;7:85-9. DOI: https://doi.org/10.18231/j.achr.2022.018

Gebremariam T, Gu Y, Singh S, Kitt TM, Ibrahim AS. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. J Antimicrob Chemother. 2021;76(10):2636-9. DOI: https://doi.org/10.1093/jac/dkab233

Personett HA, Kayhart BM, Barreto EF, Tosh P, Dierkhising R, Mara K, et al. Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity. Int J Nephrol. 2019;2019:8629891. DOI: https://doi.org/10.1155/2019/8629891

Gunathilaka SS, Keragala RK, Gunathilaka KM, Wickramage S, Bandara SR, Senevirathne IS, et al. Use of isavuconazole in mucormycosis: a systematic review. BMC Infect Dis. 2025;25(1):25. DOI: https://doi.org/10.1186/s12879-025-10439-y

Tormane MA, Laamiri G, Mroua B, Gazzah H, Beji H, Zribi S, et al. Gastric mucormycosis: a case report and review of the literature. Clin Case Rep Int. 2023;7:1603.

Orihara Y, Kurahashi S, Kamei K, Hiramatsu K. Surgical treatment of appendiceal mucormycosis in an immunocompromised patient: a case report. Surg Case Rep. 2024;10(1):159. DOI: https://doi.org/10.1186/s40792-024-01958-y

Downloads

Published

2025-10-24

How to Cite

Kumar, B. V., Rao, G. V. N., & Veena, M. (2025). A case report on gastrointestinal mucormycosis. International Journal of Advances in Medicine, 12(6), 610–613. https://doi.org/10.18203/2349-3933.ijam20253358